Bacterial Infections
Conditions
Keywords
Doripenem, DORIPED1003, Intravenous, Infection, Colonization, Prophylaxis, Pediatric, Antibiotic, Pharmacokinetics
Brief summary
The purpose of this study is to measure drug levels of doripenem in blood samples collected before and after administration of doripenem to infants less than 12 weeks of age who are hospitalized and documented, presumed to have, or are at risk for bacterial infection (s) and are undergoing treatment with intravenous (i.v.) antibiotics. Safety and tolerability will also be assessed.
Detailed description
This is a multicenter, open-label (identity of treatment is known to patient's parent/legal guardian/caregiver and to all study staff) pharmacokinetic study (a study to observe how the drug is absorbed and distributed within the body) to measure drug levels of doripenem in hospitalized but medically stable infants (term and preterm), \<12 weeks of chronological age (CA) (age since time of birth) who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with intravenous (i.v.) (administered in a vein) antibiotics. Doripenem will be administered alone at any time after the first dose of a nonstudy antibiotic is administered to the patient. Doripenem is not being used in this study to treat infection and it will not replace the patient's prescribed antibiotic(s). The duration of the study will be up to 9 days for each patient. Patients' safety will be monitored throughout the study by a safety committee who will review safety information at least once a month or after every 8 patients are enrolled and dosed. Safety evaluation will include, but will not be limited to, adverse events, clinical laboratory tests, and vital signs. A single dose of study drug (doripenem) will be administered to patients in a hospitalized setting. Patients \<8 weeks CA will receive a 5 mg/kg doripenem 1-hour i.v. infusion, and patients \>=8 weeks CA will receive an 8 mg/kg doripenem 1-hour infusion. Study drug will be administerd to the patient alone at any time after the first dose of a nonstudy antibiotic is administered to the patient.
Interventions
DRUGDoripenem
Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 12 Weeks
Healthy volunteers
No
Inclusion criteria
* Must be hospitalized, medically stable, without acute decline in physical condition in the inestigator's judgement * Documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics * Patient's weight (kg) must be within the 5th and the 95th percentile inclusive for his or her age * Parent or the patient's legally acceptable representative must have signed an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to allow the infant to participate in the study
Exclusion criteria
* Clinically significant abnormal values for hematology or clinical chemistry at screening as deemed appropriate by the investigator * Clinically significant abnormal physical examination or vital signs at screening, as deemed appropriate by the investigator * Patients who, in the investigator's judgment, have compromised renal (kidney) function including renal failure * History of clinically significant allergies to medications, especially known hypersensitivity or intolerance to carbapenems, penicillins, or other beta lactam antibiotics * Known allergy to heparin or history of heparin-induced thrombocytopenia, if an indwelling cannula (e.g., heparin lock) or central line is used * Patients concomitantly treated with or having received imipenem/cilastin within 48 hours before study drug administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Doripenem concentrations in blood samples | Before and after study drug administration for 1 day |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events | Up to Day 7 |
| Changes in clinical laboratory test results | From Day -2 to Day 1 |
| Changes in vital signs measurements | From Day -2 to Day 1 |
Countries
Belgium, United Kingdom, United States
Outcome results
None listed